Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

Klotho Neurosciences ( ($KLTO) ) has provided an announcement. On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug ...

US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical ...

U.S. stock futures declined on Thursday after ending higher on Wednesday. Futures of major benchmark indices were trading ...

Boosting Klotho protein levels in mice improves physical and cognitive aging, offering potential for future longevity ...

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Get today's Klotho Neuroscience stock news. We cover the latest Klotho Neuroscience headlines and breaking news impacting Klotho Neuroscience stock performance.

Check out our KLTO stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.